LY6E作为多发性骨髓瘤相关骨疾病的新预后生物标志物

Min Shi1, Jing Li2, Jing Wang1

  • 1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.

Scientific reports
|April 3, 2025
PubMed
概括

多发性骨髓瘤 (MM) 骨病与更高的淋巴细胞抗原6复合体 (LY6E) 表达有关. 这项研究确定LY6E是MM进展和骨病的关键驱动因素,这表明它是一个新的治疗点.